HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy

OBJECTIVE: To compare changes over 48 weeks in body fat, lipids, Metabolic Syndrome and cardiovascular disease risk between patients randomised 1∶1 to lopinavir/ritonavir (r/LPV) plus raltegravir (RAL) compared to r/LPV plus 2–3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) as se...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Allison, Moore, Cecilia L., Mallon, Patrick W. G., Hoy, Jennifer F., Emery, Sean, Belloso, Waldo H., Phanuphak, Praphan, Ferret, Samuel, Cooper, David A., Boyd, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813715/
https://www.ncbi.nlm.nih.gov/pubmed/24204757
http://dx.doi.org/10.1371/journal.pone.0077138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813715/
https://www.ncbi.nlm.nih.gov/pubmed/24204757
http://dx.doi.org/10.1371/journal.pone.0077138

Ejemplares similares